Articles On Starpharma Holdings (ASX:SPL)

The Starpharma Holdings Limited (ASX: SPL) share price rose 3% after giving its June 2019 trading update. Starpharma describes itself as a world leader in the development of dendrimer enhanced products (DEP) for pharmaceutical, life science...

This morning healthcare business Starpharma Ltd (ASX: SPL) reported a net investing and operating cash outflow for the quarter ending June 30 2019 on revenue of $626,000. For the full financial year it reported an investing and operating c...

I have recently spent some time reviewing the annual reports and announcements from S&P/ASX 200 (INDEXASX: XJO) index-listed company, Starpharma Holdings Limited (ASX: SPL) to assess the merit of buying SPL shares. Starpharma shares la...

The Starpharma Holdings Limited (ASX: SPL) share price has been a positive performer again on Thursday. In afternoon trade the dendrimer products developer’s shares have stormed almost 5% higher to $1.44. Why is the Starpharma share price...

The S&P/ASX 200 index is fighting hard to keep its head above water on Thursday. In afternoon trade the benchmark index is up slightly to 6,643.5 points. Four shares that have climbed more than most today are listed below. Here’s why t...

Super Retail Group Limited, Domain Holdings Australia Limited, Metcash Limited and Starpharma Holdings Limited have depicted a similar upward trend in generating a good YTD return. Let us have a view on the recent updates of these players l...

Australian company Starpharma (ASX:SPL) has announced a new development and option agreement with AstraZeneca to progress the development of a Dendrimer Enhanced Product version of one of the UK company's oncology medicines.